Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock

Key Points

• Meredith Cook, VP of ANI Pharmaceuticals, sold 400 shares at an average price of $88.87, decreasing her holding to 76,474 shares valued at approximately $6.8 million.
• ANI Pharmaceuticals reported a quarterly earnings per share (EPS) of $1.80, exceeding analysts' expectations of $1.42, with revenue up 53.2% year-over-year at $211.37 million.
• The stock is currently rated as a "Moderate Buy" by analysts, with a consensus price target of $84.75, reflecting a mix of buy, hold, and sell recommendations.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the company's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $88.87, for a total value of $35,548.00. Following the completion of the sale, the vice president owned 76,474 shares of the company's stock, valued at approximately $6,796,244.38. The trade was a 0.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Meredith Cook also recently made the following trade(s):

• On Monday, July 14th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $64.88, for a total transaction of $25,952.00.
• On Friday, June 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $61.37, for a total transaction of $24,548.00.

ANI Pharmaceuticals Stock Performance

ANIP traded up $1.26 on Thursday, hitting $90.00. The company had a trading volume of 604,501 shares, compared to its average volume of 623,678. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $90.23. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -116.88 and a beta of 0.61. The company's fifty day moving average price is $67.34 and its 200 day moving average price is $64.62. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. The business had revenue of $211.37 million for the quarter, compared to analysts' expectations of $187.18 million. During the same period in the previous year, the business posted $1.02 earnings per share. ANI Pharmaceuticals's quarterly revenue was up 53.2% on a year-over-year basis. Equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ANIP. Geode Capital Management LLC lifted its stake in ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock valued at $23,720,000 after acquiring an additional 3,774 shares in the last quarter. Wells Fargo & Company MN grew its holdings in ANI Pharmaceuticals by 35.7% in the 4th quarter. Wells Fargo & Company MN now owns 10,169 shares of the specialty pharmaceutical company's stock valued at $562,000 after buying an additional 2,676 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of ANI Pharmaceuticals by 34.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 4,930 shares of the specialty pharmaceutical company's stock valued at $273,000 after acquiring an additional 1,256 shares during the period. Legal & General Group Plc lifted its position in shares of ANI Pharmaceuticals by 5.6% during the 4th quarter. Legal & General Group Plc now owns 48,425 shares of the specialty pharmaceutical company's stock valued at $2,677,000 after acquiring an additional 2,585 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth $3,916,000. Institutional investors own 76.05% of the company's stock.

Wall Street Analyst Weigh In

ANIP has been the subject of several research reports. Guggenheim restated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. HC Wainwright reiterated a "buy" rating and issued a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Piper Sandler reiterated an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, Truist Financial raised their price target on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $84.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.